Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.
Artificial Intelligence In Drug Repurposing Market Value Analysis: What Growth Is Expected Over The Forecast Period?
The artificial intelligence in drug repurposing market size has seen significant expansion in recent years. It is anticipated to increase from $1.05 billion in 2025 to $1.27 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 20.3%. The historical surge in this market can be attributed to rising research and development costs within pharmaceutical development, the increasing availability of public biomedical datasets, the evolution of computational biology tools, the necessity to accelerate the time to market for therapies, and growing collaborations between pharmaceutical companies and AI startups.
The artificial intelligence in drug repurposing market is projected to experience rapid expansion in the coming years. This market is predicted to reach $2.63 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 20.1%. The anticipated growth stems from several factors, including the expansion of AI-assisted clinical decision support, the increasing application of generative AI for molecule insights, the demand for quicker repurposing during health emergencies, the broadening of real-world evidence analytics, and escalating investments in precision medicine pipelines. Key developments expected within this period encompass AI-driven drug-target matching leveraging multi-omics data, the establishment of repurposing pipelines utilizing knowledge graph discovery, the acceleration of virtual screening and trial simulations, the adoption of federated learning for collaborative cross-institution research, and the implementation of explainable AI for clinical repurposing choices.
Download A Free Sample Report For Comprehensive Market Insights:
Artificial Intelligence In Drug Repurposing Market Growth Drivers: What Factors Are Accelerating Expansion?
The increasing demand for precision medicine is projected to drive the expansion of the artificial intelligence in drug repurposing market. Precision medicine is a healthcare strategy that tailors disease prevention and treatment to an individual’s specific genes, behaviors, and environment. The growing desire for personalized treatments is accelerating the adoption of precision medicine, as patients and healthcare providers increasingly seek therapies customized to individual genetic and lifestyle profiles for better effectiveness and reduced side effects. AI-driven drug repurposing enhances precision medicine by discovering existing drugs that align with a person’s genetic or molecular characteristics, thereby enabling more accurate and personalized treatment solutions. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based nonprofit organization, the FDA granted approval for 16 personalized therapies targeting rare diseases in 2023, representing a significant increase compared to the six approvals issued in 2022. Consequently, the escalating demand for precision medicine is fueling the growth of the artificial intelligence in drug repurposing market.
#Artificial Intelligence In Drug Repurposing Market Segment Landscape And Growth Potential
The artificial intelligence in drug repurposing market covered in this report is segmented –
1) By Component: Software And Platforms, Services
2) By Technology: Machine Learning Or Deep Learning, Natural Language Processing (NLP), Knowledge Graphs And Network-Based Artificial Intelligence, Generative Artificial Intelligence And Large Language Models (LLMs), Computer Vision
3) By Deployment: Cloud-Based, On-Premises
4) By Therapeutic Area: Oncology, Neurology, Cardiovascular Diseases, Infectious Diseases, Immunology, Metabolic Disorders, Rare Diseases
5) By End-User: Pharmaceutical And Biotechnology Companies, Contract Research Organizations (CROs), Academic And Research Institutes, Healthcare Providers, Other End-Users
Subsegments:
1) By Software And Platforms: Predictive Analytics Tools, Machine Learning Frameworks, Data Integration Systems, Drug Discovery Platforms, Clinical Trial Simulation Tools
2) By Services: Consulting Services, Data Management Services, Model Training And Optimization Services, Implementation And Integration Services, Support And Maintenance Services
Artificial Intelligence In Drug Repurposing Market Trends: What Is Shaping Future Industry Growth?
Major companies operating in the artificial intelligence in drug repurposing market are concentrating on integrating advanced technologies into drug repositioning, specifically computational drug repositioning systems. Such systems represent technology-driven platforms that leverage artificial intelligence, machine learning, and data mining to systematically analyze existing drugs, compounds, and biological data, thereby identifying new therapeutic indications for current medications through data-driven analysis of literature and biological information. For instance, in November 2023, Tempus, a US-based provider of AI-based precision medicine solutions, announced a multi-year strategic collaboration with Recursion, a US-based clinical stage biotechnology company, with a valuation of up to $160 million over five years. This partnership provides Recursion with access to Tempus’ extensive library of de-identified, multimodal oncology data to support biomarker-driven therapeutic development. By utilizing Tempus’ large-scale patient datasets alongside Recursion’s AI-enabled discovery capabilities, the alliance strengthens oncology drug repurposing initiatives, illustrating how sophisticated computational platforms combined with real-world clinical data can accelerate the discovery of new treatment opportunities.
Artificial Intelligence In Drug Repurposing Market Competitive Landscape: Who Are The Leading Companies?
Major companies operating in the artificial intelligence in drug repurposing market are IBM Corporation, Evogene Ltd., Ginkgo Bioworks Holdings Inc., BioAge Labs Inc., Insilico Medicine Inc., BostonGene Corporation, ISOMORPHIC LABS, Recursion Pharmaceuticals Inc., Deep Genomics Inc., Healx Ltd., Owkin Inc., BullFrog AI Holdings Inc., Aicura Medical GmbH, Kantify, Ignota Labs Ltd., OrphAI Therapeutics, Nabla Bio, Atomwise Inc., BioXcel Therapeutics Inc., Graph AI.
Access The Complete Artificial Intelligence In Drug Repurposing Market Report:
Artificial Intelligence In Drug Repurposing Market Leading Geography: Which Region Generates The Most Revenue?
North America was the largest region in the artificial intelligence in drug repurposing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the artificial intelligence in drug repurposing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Wasay has over a decade of experience in market research, data modelling, and analytics, with prior experience at GlobalData and Decision Tree Consulting Services. At The Business Research Company , he leads research operations across syndicated studies, customized consulting engagements, and the Global Market Model platform. His professional experience includes supporting organizations such as Boston Consulting Group, KPMG, and Ernst & Young. Wasay holds a degree in Electronics and Communications Engineering, postgraduate management qualifications from International Management Institute Belgium and Indian School of Business and Entrepreneurship, and completed the Integrated Program in Business Analytics from Indian Institute of Management Indore.
